• Company
    About us Management Team Board of Directors Investors
  • Our Focus
    Our Focus Managed Access Programme
  • Research Areas (current)
  • News (current)
  • Careers
    Current Vacancies GDPR Transparency Statement For Candidates
  • Contact
    Our Details Medical Information Product Safety Business Development

Select a Location

Europe

  • France
  • Germany, Austria & Switzerland
  • Italy
  • Spain
  • United Kingdom

Americas

  • United States
Your browser does not support the video tag.

Courage
For Life

Latest News

EUSA Pharma Announces Appointment of Carsten Thiel as New Chief Executive Officer

30/03/2021

Read More …

SYLVANT® (siltuximab) Recommended by the National Comprehensive Cancer Network® (NCCN®) as the Preferred Treatment Option for Patients with Idiopathic Multicentric…

25/02/2021

Read More …

EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for SYLVANT® (Siltuximab for Injection) in China…

25/01/2021

Read More …
All News

Company

  • About us
  • Management Team
  • Board of Directors
  • Investors

Our Focus

  • Our Focus
  • Managed Access Programme

Contact

  • Our Details
  • Product Safety
  • Research Grants
  • Business Development

Legal

  • Terms & Conditions
  • Privacy Policy
  • Cookie Policy
  • Anti-modern Slavery Statement
  • Ethics and Compliance Reporting
  • Risk Assessment
  • HCP Privacy Notice
  • © 2021 EUSA Pharma
  • GL-NPS-2000013
  • Date of prep: October 2020
You are about to leave the United Kingdom area of eusapharma.com

Medical practices and regulations can vary from one country to another. As a result, the medical information provided in the area which you are about to visit may not be appropriate for product use in your country.

If you wish to continue to the area of eusapharma.com, please click 'Proceed'.

Cancel Proceed
You are now leaving EUSAPharma.com

The link you have clicked will take you to an external site not owned or controlled by EUSA Pharma.

Cancel Proceed